Macrogen seeks to help everyone enjoy a long and healthy life by utilizing genomic data
Our goal is to make DNA blueprints
available to people around the world.
After accomplishing the "Human Genome Map" by mankind in the 21st century through the genome project, the medical paradigm has shifted from a treatment-centered approach to disease prevention and health care.
As the $1,000 genome has been realized, human society is rapidly advancing
into the era of precision medicine that is capable of predicting, diagnosing,
and treating diseases based on big data that integrates medical and
genomic information. Recognizing the importance of genomic medicine as a key to
innovative change in the medical paradigm and the realization of precision medicine,
we have made outstanding progress in research in the field of genomic analysis.
Particularly, we became the fourth company in the world to analyze the entire
genome of Koreans with the individual genome analysis results in 2009 and
the first when it comes to Northern Asian genome analysis results. In 2016,
we managed to overcome the limitations of the existing international standard
genome and achieve the world's most complete Asian standard genome
applicable to future precision medicine.
Macrogen has constantly evolved and adapted to the changing market for
the last two decades and is prepared to become the global No. 1 company
in the "Genome Foundry" industry by expanding its domestic and international
genome centers' operations based on the new management structure and
the mid-to-long term vision called "Macrogen 2.0." Macrogen is currently striving
to take another leap in the clinic business by providing health check-up services
tailored to each person's genes for disease predictions at its medical institutions,
including Macrogen Medical Foundation's Gene Health Check-up Center.
While vertically integrating our business areas including the upstream and
downstream businesses related to DNA analysis, Macrogen, a healthcare company
with a pivot on "wellness," will continue to expand our global network. Furthermore,
Macrogen will continue making progress toward the goal of empowering humans to
achieve longevity without diseases by tapping into the digital transformation in
healthcare empowered by the convergence of big data, including genomic data,
and AI-driven analysis technologies.
Chairman of Macrogen Jeong-Sun Seo
1980PhD in Biochemistry and Molecular Biology, Seoul National University College of Medicine
1976M.D., Seoul National University College of Medicine
1997 - PresentChairman & Founder, Macrogen Inc., Republic of Korea
2017 - PresentDistinguished Professor, Seoul National University Bundang Hospital, Republic of Korea
2017 - PresentChairman, Gong-Wu Genome Information Foundation (G2IF), Republic of Korea
2018 - PresentChairman, Macrogen Medical Foundation, Republic of Korea
2012 - PresentEditor, PLOS One Journal, USA
2009 - 2020President, Korea Biotechnology Industry Organization, Republic of Korea
2005 - PresentChairman, Biomedical hub advisory committee of IFEZ, Republic of Korea
2005 - PresentMember, American Society for Biochemistry and Molecular Biology (ASBMB), USA
2004 - PresentChairman of the Board, Macrogen Inc., Republic of Korea
2003 - PresentMember, The Korean Academy of Science and Technology (KAST), Republic of Korea
1997 - PresentEMM Journal Editor
1997 - PresentCharter Member, International Molecular Biology Network (IMBN), Republic of Korea
1997 - PresentMember of New York Academy of Science, USA
1997 - 2017Director, ILCHUN Genomic Medicine Institute (GMI), SNU MRC, Republic of Korea
1983 - 2017Professor, Seoul National University, Republic of Korea
2009President, Korean Society for Biochemistry and Molecular Biology (KSBMB), Republic of Korea
2009President, The Korean Society of Medical Biochemistry and Molecular Biology, Republic of Korea
2008President, The Korean Society of Medical Biochemistry and Molecular Biology, Republic of Korea
2007 - 2009President, Korea Bio Venture Association, Republic of Korea
2005President, Korea Genome Organization (KOGO), Republic of Korea
2001 - 2002Scientific Advisor, Ministry of Health & Welfare, Republic of Korea
2000 - 2004CEO, Macrogen Inc., Republic of Korea
Education & Experience
2022 - PresentCEO, Macrogen Inc.
2012 - 2021Director/CTO, Macrogen Bioinformatics Institute
2009 - 2011Senior Researcher, BMDRC(Bioinformatics and Moleculer Design Research Center)
2003 - 2009Visiting/Researcher Fellow, NCI(National Cancer Institute)
2001 - 2002Senior Researcher, KRIBB(Korea Research Institute of Bioscience and Biotechnology)
1998Ph.D, Bioscience, KAIST
1992M.D, Bio-engineering, KAIST
1990B.S, Genetic Engineering, Kyungpook National University
Macrogen, an iconic Korean biotech company, is a global leader in genomic analysis
Founded on June 5, 1997, Macrogen Inc., has since become established as a global leader in precision medicine with clients from more than 18,000 research institutions in 153 countries around the world through continuous research and innovation in the rapidly changing biotechnology industry. Equipped with unrivaled technological expertise, backed by talented human resources and extensive experience, and cutting-edge genomic analysis infrastructure, Macrogen offers the best available biotech total solutions for its global client base.
Macrogen was also the first in the industry to obtain PIMS (personal information management system) certification for its outstanding effort to enhance information security and personal data protection.
In addition, the company has done its best to share its cutting-edge technologies with others in the industry through constant technological cooperation with other leading gene sequencing companies.
Macrogen is preparing to take the
next step forward – shifting from being a technology-centered company to a customer-centered company.
Utilizing the technological expertise and corporate reputation that it has built over the years, Macrogen now wants to shift its focus to growing its new customer-centered business by including services such as high value-added clinical diagnosis and personal genomics. To that end, Macrogen has already built its very own Precision Medicine Center network equipped with world-class clinical diagnostic laboratories and continues to develop and launch clinical diagnostic services based on the latest genomic analysis technologies for cancer diagnoses, among others.
Furthermore, Macrogen has implemented localization strategies in key overseas markets through its US subsidiary (Psomagen, Inc.) and its subsidiaries in Europe and Japan in a bid to expand its global presence throughout the world with the launch of DTC genetic testing and microbiome analysis services.